IMR Press / FBL / Volume 18 / Issue 3 / DOI: 10.2741/4165

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

New insights into the gene function of osteoporosis

Show Less
1 Department of Endocrinology and Metabolism, Shanghai First People’s Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Shanghai 200080, China
Academic Editor:Fei He
Front. Biosci. (Landmark Ed) 2013, 18(3), 1088–1097;
Published: 1 June 2013
(This article belongs to the Special Issue Cellular immunology and stem cell biology)

Osteoporosis is a common disease characterized by low bone mass, microarchitectural deterioration of bone tissue and an increased risk of fracture. Population-based and case-control studies have identified polymorphisms in several candidate genes that have been associated with bone mass or osteoporotic fracture, including the vitamin D receptor (VDR), estrogen receptor (ER), oestrogen α receptor (ESR), transforming growth factor (TGF)-β, and type I collagen. The Wnt signaling and receptor activator of nuclear factor κB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathways have been shown to play critical roles in determining bone mass and strength. An important aim of future work will be to further clarify the mechanisms involved in the interaction between candidate genes and environmental variables leading to osteoporosis via signaling pathways in individual patients. Hence preventative therapy, particularly gene therapy, could be targeted in patients at greatest risk of osteoporosis.

Bone Mineral Density
Gene Therapy
Back to top